Document is current
Any future updates will be listed below
-
Authors
Conry, Michael
Ostrovnaya, Irina
Kemel, Yelena
Sinha, Saloni
Baughn, Linda B.
Avery, Brian
Maclachlan, Kylee
Groner, Victoria
Banaszak, Lauren
Norman, Aaron
Boddicker, Nicholas J.
Clay-Gilmour, Alyssa
Kumar, Shaji
Kim, Ellen
Dandiker, Sita
Waghmare, Mitul
Slager, Susan
Sborov, Douglas W.
Garber, Judy
Brown, Elizabeth E.
Hildebrandt, Michelle
Hari, Parameshwaran
Camp, Nicola
Vachon, Celine
Usmani, Saad
Offit, Kenneth
Joseph, Vijai
-
Funding
Funding for this research was provided by:
National Institutes of Health (U01CA257679)
National Institutes of Health (U01CA249955 , R01CA186646)
National Institutes of Health (R01CA134674)
National Institutes of Health (R21CA209533)
- License Information
-
More Information
Article History
Received: 13 October 2025
Accepted: 24 December 2025
First Online: 6 January 2026
Declarations
:
: The study is approved by the institutional review board (18–339) at MSKCC. IRBs at other institutions approved sample acquisitions as described in the Supplementary Information.
: Dr. Douglas W Sborov declares Research support from Pfizer and advisory/consultation with Keosys, Parexel, Pfizer, Abbvie, Janssen, Bristol Myer Squibb, GlaxoSmithKline, Legend Biotech, Opna Bio, Arcellx, Genentech, Sanofi. Dr. Usmani declares Professional Services and Activities with AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., Pfizer, Inc., and Regeneron Pharmaceuticals, Inc.
